• Explore /
  • Poster
  • / Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

Ecaterina Dumbrava

Ecaterina Elena Dumbrava

The University of Texas MD Anderson Cancer Center, Houston, TX

Ecaterina Elena Dumbrava , Geoffrey Shapiro , Johanna C. Bendell , Timothy A. Yap , Rinath Jeselsohn , Denise M. Lepley , Sabrina Hurley , Kevin K. Lin , Michelle Liao , Jenn Habeck , Aaron Enke , Erika P. Hamilton

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Track

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Sub Track

Small Molecules

Clinical Trial Registration Number

NCT03992131

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr 3102)

DOI

10.1200/JCO.2021.39.15_suppl.3102

Abstract #

3102

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Piotr Jan Wysocki

First Author: Severine Guiu Lahaye

First Author: Joseph W. Kim

First Author: Joseph W. Kim